Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

The United States is witnessing a rise in cases of Powassan virus disease, a rare but potentially deadly illness transmitted through tick bites. Unlike many other tick-borne diseases, Powassan virus can be transmitted within 15 minutes of a tick attaching to the skin, making prevention and awareness especially important.

According to the US Centers for Disease Control and Prevention (CDC), tick exposure can occur throughout the year, although ticks are most active during the warmer months between April and September.

Emergency physician Dr. Rick Pescatore recently highlighted the growing threat in a TikTok video post, warning that many people remain unaware of the virus despite its severe health consequences.

"There's a new and deadly tick virus that's spreading across the United States, and you probably haven't heard about it," he said.

Pescatore emphasized the seriousness of the infection, noting that "about one in 10 people with severe disease die, while around half of survivors may experience permanent neurological damage". He also claimed that reported cases have increased steadily over the past decade.

Several state health departments have urged residents to take precautions after reporting cases of the rare disease.

In one recent case, a 66-year-old man from New Hampshire was hospitalized for several weeks after contracting the virus. After initially being admitted to Concord Hospital, he was later transferred to Massachusetts General Hospital for specialized care.

What Is Powassan Virus?

Also read: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant

The Powassan virus is named after the town of Powassan in Ontario, Canada, where it was first identified in 1958. It belongs to the flavivirus family, which also includes viruses that cause Zika, dengue, and West Nile fever.

The virus is primarily spread by the black-legged tick (Ixodes scapularis), also known as the deer tick, which is also responsible for transmitting Lyme disease.

However, unlike Lyme disease—which generally requires a tick to remain attached for more than 24 hours before transmission—Powassan virus can be transmitted in as little as 15 minutes, according to the Massachusetts Department of Public Health.

Symptoms of Powassan Virus Infection

Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn

Symptoms typically develop between seven and 30 days after a tick bite and may include:

• Fever
• Headache
• Vomiting
• Weakness
• Confusion
• Loss of coordination
• Seizures
• Difficulty speaking

These complications can lead to long-term neurological damage. According to Yale Medicine, approximately 10 per cent of severe cases are fatal, while nearly 50 per cent of survivors experience lasting neurological problems.

No Vaccine or Treatment Available

One of the most concerning aspects of the Powassan virus is that there is currently no vaccine or antiviral treatment available.

Unlike Lyme disease, which can be treated with antibiotics, Powassan virus has no specific cure. Medical care focuses on managing symptoms and supporting patients with severe disease.

As a result, prevention remains the most effective defense against infection.

How to Prevent Tick Bites

The CDC and the National Institutes of Health (NIH) recommend the following measures to reduce the risk of tick bites:

• Wear long-sleeved shirts and long pants when outdoors
• Choose light-colored clothing to make ticks easier to spot
• Tuck pants into socks or seal gaps in clothing
• Use insect repellents containing DEET, picaridin, or permethrin
• Stay in the center of hiking trails and avoid brushing against vegetation
• Check your body, clothing, pets, and outdoor gear for ticks after spending time outside
• Shower and wash clothing in hot water soon after returning indoors

If you find a tick attached to your skin, remove it promptly using fine-tipped tweezers.

Amid the ongoing Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus diseases, a group that includes all Ebola and Marburg virus infections.

Ebola and Marburg diseases are severe, often fatal illnesses that have caused repeated outbreaks across Africa. Since the discovery of the Marburg virus in 1967, there have been 72 documented outbreaks of Ebola and Marburg diseases.

There are currently no licensed vaccines and treatments for Marburg virus disease, as well as Bundibugyo and Sudan virus diseases. Thus, the WHO emphasized that early supportive care remains one of the most effective ways to improve survival.

"The current Bundibugyo virus outbreak is a stark reminder of the need for diligent, holistic and person-focused medical care to save lives and preserve human dignity. We encourage governments and authorities to integrate these new recommendations into preparedness and outbreak response to ensure high-quality care for everyone," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

Also read: Ebola Bundibugyo Outbreak: UK Scientists Identify 23 Unique Mutations

What Do The New Guidelines Recommend?

The WHO has previously published disease-specific guidance on Ebola care and therapeutics. However, the newly released guidelines are the first to provide a comprehensive framework covering all filovirus diseases, including Ebola and Marburg.

Developed through consultations with global experts and based on the latest scientific evidence, the guidelines contain 16 evidence-based recommendations focused on improving supportive care and reducing mortality.

The recommendations are designed to help frontline healthcare workers:

• Identify clinical deterioration early
• Manage dehydration and shock effectively
• Improve patient monitoring
• Deliver critical supportive interventions safely
• Provide structured follow-up care for survivors

Key Recommendations include:

• Prioritizing Laboratory Testing
• Rapid Treatment of Dehydration
• Early Management of Shock
• Treatment should be guided by continuous monitoring of vital signs and indicators of tissue perfusion.
• Treat Secondary Bacterial Infections
• Provide Long-Term Follow-Up Care

The WHO also recommended structured after-care programs for survivors to support recovery, improve long-term well-being, and reduce the risk of infections linked to viral persistence after recovery.

Supportive Care Remains Critical

For Bundibugyo virus disease and other filovirus infections, WHO stressed that early recognition, rapid referral, and optimized supportive care remain the foundation of patient management.

Effective supportive care can reduce complications, improve survival, and provide the basis for evaluating potential antiviral treatments through future clinical research.

Ebola Outbreak Faced Major Contact-Tracing Gaps

Meanwhile, the Africa Centers for Disease Control and Prevention (Africa CDC) has raised concerns about significant weaknesses in contact-tracing efforts during the ongoing outbreak.

According to Africa CDC Director-General Dr. Jean Kaseya, more than 28,000 people who have been in contact with confirmed Ebola patients are currently not being monitored.

Responders should be tracking approximately 33,080 contacts, but only 4,112 are being actively followed, he said during a high-level meeting.

The agency warned that the outbreak is spreading at a pace that surveillance systems are struggling to keep up with.

Read More: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study

Ebola: More Than 800 Confirmed Cases

As per latest update till June 15, there are 827 confirmed Ebola cases linked to the outbreak in the Congo and 196 confirmed death.

Health officials estimate that each infected person may have come into contact with around 40 other individuals, creating a large pool of people at risk of infection.

Because Ebola can take up to 21 days for symptoms to appear, all identified contacts should ideally be monitored throughout the incubation period.

Africa CDC officials cautioned that without stronger surveillance and contact-tracing efforts, controlling the outbreak will become increasingly difficult, despite advances in clinical care and patient management.

Yet another study has highlighted the cardiovascular benefits of COVID-19 vaccination, particularly among older adults and people with underlying health conditions.

A new study involving nearly one million people, published in the journal JAMA Internal Medicine, found that COVID vaccination reduced the risk of major cardiovascular events associated with the virus—including heart attacks, strokes, and hospitalizations due to heart disease—by about 40 per cent.

The protective effect was most pronounced among adults aged 75 years and older, as well as individuals with pre-existing conditions such as cardiovascular disease, diabetes, and chronic lung disease.

The findings add to a growing body of evidence suggesting that COVID vaccines offer benefits beyond preventing severe infection.

Researchers also found that vaccination modestly reduced the risk of cardiovascular events, hospitalizations, and deaths from all causes, including those not directly linked to COVID.

"Extrapolating these estimates to a population of one million people, vaccination could plausibly be associated with averting approximately 2,370 major cardiovascular events and 1,580 deaths over an eight-month period," the study noted.

"It tells us that these vaccines have actually brought beneficial effects even in people who don't really know that they have contracted COVID-19," said Dr. Ziyad Al-Aly, physician-scientist and senior clinical epidemiologist at Washington University in St. Louis and co-author of the study, the Washington Post reported.

What Did the Study Find?

Also read: Trying to Quit Tobacco? Yoga Could Improve Your Chances, Suggests Study

Several previous studies have shown that COVID vaccination lowers the risk of heart attacks and strokes. However, researchers wanted to determine whether those benefits continued in the years after the onset of the pandemic, especially as both the virus and vaccine formulations evolved.

"Vaccine formulations have changed, and also the virus itself has changed over time," Al-Aly said. "But we found that the more recent vaccine formulations still protected against heart conditions."

The study analyzed nearly one million veterans receiving care through the US Department of Veterans Affairs health system between 2024 and 2025.

The participants were divided into two groups: individuals who received only the seasonal influenza vaccine and those who received both the flu vaccine and the updated COVID-19 vaccine during the same season. The analysis included multiple vaccine types, including mRNA vaccines and the Novavax vaccine.

Lower Risk of Heart Conditions

Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn

Participants were followed for approximately eight months. The results showed that people who received a COVID vaccine had a 37.7 per cent lower risk of developing COVID-associated cardiovascular complications.

Vaccinated individuals were also about 6 per cent less likely to experience severe cardiovascular events overall, including those not directly linked to COVID-19 infection.

In addition, vaccination was associated with:

• A 7 per cent reduction in all-cause hospitalizations
• A 7 per cent reduction in all-cause mortality
• Fewer severe cardiovascular events overall

While these percentages may appear modest, researchers emphasized that the public health impact is substantial.

According to Al-Aly, for every 10,000 people vaccinated, the findings translate into preventing approximately:

• 23 major cardiovascular events
• 30 hospitalizations
• 16 deaths

Benefits Outweigh Risk

COVID-19 vaccines have previously been linked to rare cases of myocarditis and pericarditis, conditions involving inflammation of the heart muscle and its surrounding lining.

However, experts note that these cases are uncommon and generally mild. Public health authorities continue to maintain that the benefits of vaccination far outweigh the potential risks.